The Future of Aging and Longevity - Flipbook - Page 28
The Longevity Investor:
Where Agetech and Biotech Converge
Abby M. Levy
Alan Patricof
Managing Partner and
Founder, Prime琀椀me Partners
Chairperson and Co-Founder,
Prime琀椀me Partners
hen we launched Prime琀椀me Partners
in 2020, there was a clear divide
between agetech (technologies
to improve the way we experience aging) and
longevity science (the biotech discoveries that
promise to reverse cellular aging). Prime琀椀me’s
investment focus—to improve how we age—
resulted in 38 investments into early-stage
agetech start-ups.
We have been closely watching the “adul琀椀ng”
of longevity science, encouraged by the Food and
Drug Administra琀椀on (FDA)’s recent recogni琀椀on of
lifespan extension as a valid clinical endpoint and
AI accelera琀椀ng biomarker discovery, which then
feeds into longevity drug discovery. At the same
琀椀me, consumer demand for longevity solu琀椀ons
is ramping up with the accessibility of longevity
drugs such as GLP-1s (15 percent of Americans
have tried the wonder drug), the penetra琀椀on of
W
24
wearable biomarker trackers such as Oura and
WHOOP, and the media ascension of longevity
doctors.18 Private investment in longevity science
nearly doubled since 2024, reaching $8.5 billion
across 325 deals.19
While Prime琀椀me Partners doesn’t invest
directly in FDA-regulated spaces, we believe the
next decade of opportunity lies at the intersec琀椀on
of agetech and longevity biotech.
Precision diagnos琀椀cs and predic琀椀ve AI lead a shi昀琀
toward preventa琀椀ve medicine.
Everybody loves diagnos琀椀cs: “Always on”
ambient tracking leads to early detec琀椀on, which
then leads to disease preven琀椀on. Oura, WHOOP,
and Garmin are moving well beyond step coun琀椀ng
into serious physiological tracking. Glucose
monitors, once reserved for diabe琀椀cs, are now
used far more broadly to monitor overall health.
MIL K EN I N S T I T U T E | T H E FU T U RE O F AGI N G A N D LO N GEV I TY
